The use of onabotulinumtoxinA (onabotA, Botox) for the treatment of overactive bladder comes with several important considerations. The use of onabotulinumtoxinA (onabotA, Botox) for the treatment of ...

“Like any disease state, you want to make sure you have the right diagnosis; otherwise, you're not going to have a successful treatment plan," says Karyn S. Eilber, MD. The landscape of treatment for ...

“We have to understand as providers that we're not going to be the one and only conduit for this information anymore, which is a good thing, to be honest," says Ian Metzler, MD, MTM. There are ...

Video content above is prompted by the following: Evolution of BPH Treatment Outcomes Dr Christopher Kelly discusses the evolution of patient outcomes with different benign prostatic hyperplasia (BPH) ...

Nadofaragene firadenovec achieved a 75% complete response rate at 3 months in Japanese patients with high-risk BCG-unresponsive NMIBC. The therapy demonstrated a favorable safety profile, with no ...

We preview several noteworthy P2 presentations in the urologic oncology space. The American Urological Association (AUA) will try its luck in Las Vegas, Nevada for its 2025 annual meeting. Taking ...

The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey. Receiving an initial diagnosis of renal cell carcinoma (RCC) is often an overwhelming ...

“You absolutely need to have a CT scan prior to the surgery to best identify and really intimately understand the kidney’s anatomy," says Perry Xu, MD. When it comes to performing percutaneous ...

Combination of BWL and ultrasonic propulsion effectively fragments and repositions small renal stones in awake patients without anesthesia. The procedure achieved a 71% success rate in reducing stone ...

A panelist discusses how both the ARCHES and ARANOTE trials demonstrated significant improvements in radiographic progression-free survival with their respective novel hormonal therapies (enzalutamide ...

There is also a need to improve multidisciplinary care, according to Ekene Enemchukwu, MD. Knowledge about genitourinary syndrome of menopause (GSM) and the benefits of vaginal estrogen is lacking, ...

Merrill discusses the evolving non–muscle invasive bladder cancer treatment space. Expanded access programs (EAPs), such as a recently FDA-authorized EAP in which ImmunityBio is partnering with the ...